Ingrid Kamerling

Ingrid Kamerling


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Vaccine
Verified
Journal Article
Open access
PVPauline Verdijk
Pauline Verdijk
JPJohan L. van der Plas
Johan L. van der Plas
EBEmilie M.J. van Brummelen
Emilie M.J. van Brummelen
RJRienk E. Jeeninga
Rienk E. Jeeninga
CHCornelis De Haan
Cornelis De Haan
IKIngrid Kamerling
Ingrid Kamerling
Human respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in early infancy and in elderly. A pediatric vaccine against RSV would not only prevent morbidity and mortality amongst infants and young children but could also reduce transmission to elderly. The RSVΔG vaccine consists of a live-attenuated RSV that lacks the G attachment protein. RSVΔG is severely impaired in binding to host cells and exhibits reduced infectivity in preclinical studies. Intranasal immunization of cotton rats with RSVΔG vaccine protected against replication of wildtype RSV, without inducing enhanced disease. We performed a first-in-human trial with primary objective to evaluate safety and shedding of RSVΔG (6.5 log10 CCID50) after intranasal administration. Healthy adults aged between 18 and 50, with RSV neutralizing serum titers below 9.6 log2, received a single dose of either vaccine or placebo (n = 48, ratio 3:1). In addition to safety and tolerability, nasal viral load, and systemic and humoral immune responses were assessed at selected time points until 4 weeks after immunization. Intranasal administration of RSVΔG was well tolerated with no findings of clinical concern. No infectious virus was detected in nasal wash samples. Similar to other live-attenuated RSV vaccines, neutralizing antibody response following inoculation was limited in seropositive adults. A single dose of 6.5 log10 CCID50 of RSVΔG was safe and well-tolerated in seropositive healthy adults. RSVΔG was sufficiently attenuated but there were no signs of induction of antibodies. Safety and immunogenicity can now be explored in children and eventually in seronegative infants. Clinical trial register: NTR7173/EudraCT number 2016-002437-30.

21 May 2021 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
KHKim Henriksen
Kim Henriksen
KBKaren Broekhuizen
Karen Broekhuizen
WBWadim M I de Boon
Wadim M I de Boon
MKMorten A Karsdal
Morten A Karsdal
ABAsger R Bihlet
Asger R Bihlet
IKIngrid Kamerling
Ingrid Kamerling

25 March 2021 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
PDF file
CBCécile L. Berends
Cécile L. Berends
LPLisa Pagan
Lisa Pagan
MEMichiel J. van Esdonk
Michiel J. van Esdonk
NKNaomi B. Klarenbeek
Naomi B. Klarenbeek
KBKirsten R. Bergmann
Kirsten R. Bergmann
IKIngrid Kamerling
Ingrid Kamerling
The strict intake regimen of cysteamine bitartrate formulations, associated with side effects, is a concern for the treatment compliance in cystinosis therapy. Therefore, there is a need for a cysteamine formulation with an improved pharmacokinetic profile. This study investigated the pharmacokinetics, safety and tolerability of a new sustained‐release cysteamine dosage form, PO‐001, in healthy volunteers. This was a randomized, investigator‐blinded, three‐way cross‐over study to compare single doses (600 mg) of PO‐001 with Cystagon® (immediate‐release) and Procysbi® (delayed‐release). Collected blood samples were analyzed for plasma cysteamine concentrations and pharmacokinetic parameters were estimated by noncompartmental analysis. In addition, plasma cysteamine concentrations were analyzed using a population pharmacokinetic approach using NONMEM®. Pharmacokinetics showed clear sustained‐release characteristics of PO‐001 over time with a lower Cmax and longer Tmax compared to Cystagon® and Procysbi®. All treatment‐emergent adverse events were of mild severity, with the exception of two subjects who reported moderate severity gastrointestinal problems including vomiting and diarrhea, which were related to Cystagon® intake. Population PK simulations showed a favourable PK profile based on Cmax and Ctrough concentrations at steady state. In conclusion, a single dose of 600 mg PO‐001 was well tolerated with no findings of clinical concern. This new cysteamine bitartrate formulation showed pharmacokinetics of a sustained‐release formulation, which may be beneficial for the treatment of cystinosis patients. This study supports advancing this type of sustained‐release formulation into a subsequent study to confirm reduced dosing frequency with efficient control of white blood cells (WBCs) cystine levels. Netherlands Trial Registry (NTR) (NL67638.056.18).

20 December 2019 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
JPJohan L. Van Der Plas
Johan L. Van Der Plas
PVPauline Verdijk
Pauline Verdijk
EBEmilie M. J. Van Brummelen
Emilie M. J. Van Brummelen
RJRienk E. Jeeninga
Rienk E. Jeeninga
MRMeta Roestenberg
Meta Roestenberg
IKIngrid Kamerling
Ingrid Kamerling
One of the main challenges in early clinical research with respiratory syncytial virus (RSV) live-attenuated vaccines (LAVs) is to assess immunogenicity in healthy adults. Healthy adults will have preexisting levels of serum neutralizing antibodies that could prematurely neutralize the LAV and underestimate the potential effect of the vaccine on the immune system. Data on prevalence and distribution of virus neutralizing titers (VNTs) in healthy adults is limited and there is no absolute threshold for protection against RSV-infection that can serve as an eligibility criterion in early phase trials. We assessed the RSV-specific serum VNT in healthy adults outside the Dutch RSV-Season in two clinical studies performed in 2017 (exploratory study, n = 100) and 2018 (first-in-human LAV-study, n = 190) using the same neutralizing assay. Our findings show that the prevalence and distribution of serum VNT was overall consistent in the two clinical studies. Log2 VNTs were normally distributed, distributions of VNTs were similar and there was no statistical difference in mean log2 VNT for both studies (p = .3). Serum VNTs were comparable during the 6 months of screening in the FIH LAV-study. Our findings will help to determine a cutoff serum VNT to be used as an eligibility criterion in future early phase clinical trials.

13 February 2024 in Biologicals
Verified
Journal Article
Open access
MKMelissa Kapulu
Melissa Kapulu
Lucinda Manda-TaylorLucinda Manda-Taylor
Lucinda Manda-Taylor
SBShobana Balasingam
Shobana Balasingam
GMGary Means
Gary Means
MMMikal Ayiro Malungu
Mikal Ayiro Malungu
PNPieter Neels
Pieter Neels
Challenge agent, CHIM ethics, environmental safety in CHIM, recruitment, community engagement, advertising and incentives, pre-existing immunity, and clinical, immunological, and microbiological endpoints. The fourth CHIM meeting focused on CHIM studies being conducted in endemic countries. Over the last ten years we have seen a vast expansion of the number of countries in Africa performing CHIM studies, as well as a growing number of different challenge organisms being used. Community and public engagement with assiduous ethical and regulatory oversight has been central to successful introductions and should be continued, in more communityled or community -driven models. Valuable initiatives for regulation of CHIMs have been undertaken but further capacity building remains essential.

20 August 2021 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
PDF file
JVJosephina P. M. Vrouwe
Josephina P. M. Vrouwe
IKIngrid Kamerling
Ingrid Kamerling
MEMichiel J. van Esdonk
Michiel J. van Esdonk
JMJosbert M. Metselaar
Josbert M. Metselaar
FSFrederik E. Stuurman
Frederik E. Stuurman
SOSusanne Osanto
Susanne Osanto
Dexamethasone has antitumor activity in metastatic castration resistant prostate cancer (mCRPC). We aimed to investigate intravenous liposome‐encapsulated dexamethasone disodium phosphate (liposomal dexamethasone) administration in mCRPC patients.In this exploratory first‐in‐man study, patients in part A received a starting dose of 10 mg followed by five doses of 20 mg liposomal dexamethasone at 2‐week intervals. Upon review of part A safety, patients in part B received 10 weekly doses of 18.5 mg. Primary outcomes were safety and pharmacokinetic profile, secondary outcome was antitumor efficacy.Nine mCRPC patients (5 part A, 4 part B) were enrolled. All patients experienced grade 1–2 toxicity, one (part B) patient experienced grade 3 toxicity (permanent bladder catheter‐related urosepsis). No infusion‐related adverse events occurred. One patient had upsloping glucose levels ≤9.1 mmol/L. Trough plasma concentrations of liposomal‐ and free dexamethasone were below the lower limit of quantification (LLOQ) in part A, and above LLOQ in three patients in part B (t1/2 ~50 h for liposomal dexamethasone), trough concentrations of liposomal‐ and free dexamethasone increased toward the end of the study. In seven of nine patients (78%) patients, stable disease was observed in bone and/or CT scans at follow‐up, and in one (part B) of these seven patients a >50% PSA biochemical response was observed.Bi‐ and once weekly administrations of IV liposomal dexamethasone were well‐tolerated. Weekly dosing enabled trough concentrations of liposomal‐ and free dexamethasone >LLOQ. The data presented support further clinical investigation in well‐powered studies.Clinical trial registration: ISRCTN 10011715.